Skip to content
ppp787787787

Drawing based on the label description. No photo yet.

“Pink, film coated, round shaped biconvex tablet, debossed with "p" on one side and "787" on the other”

p 787 pill

Pill with imprint p 787 is pink, round, 10 mm and has been identified as Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide 40 mg / 5 mg / 12.5 mg. It is used for high blood pressure. It is supplied by Par Health Usa, LLC.

Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide 40 mg / 5 mg / 12.5 mg

Imprint
p 787
Strength
Olmesartan Medoxomil 40 mg / Amlodipine 5 mg / Hydrochlorothiazide 12.5 mg
Used for
High blood pressure
Color
Pink
Shape
Round
Size
10 mm
Score
No score line
Form
Tablet, film coated
Manufacturer
Par Health Usa, LLC
Drug class
ARB (blood pressure medicine)
NDC
49884-787, 49884-787-11, 49884-787-09

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide pills and guides

What is Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide used for?

Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide is used for high blood pressure.

Medicine type
ARB (blood pressure medicine); calcium channel blocker (blood pressure and heart medicine)
Official uses from the US prescribing label

Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Limitations of Use

This fixed combination drug is not indicated for the initial therapy of hypertension.

From the FDA-approved label on DailyMed (published Sep 29, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows p and the other side shows 787.
  • It is pink, round, 10 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Olmesartan Medoxomil, Amlodipine Besylate, Hydrochlorothiazide

Inactive: Cellulose, Microcrystalline, Starch, Corn, Croscarmellose Sodium, Magnesium Stearate, Titanium Dioxide, Polyethylene Glycol 1000, Talc

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide pills